Late-breaking data from landmark coapt™ trial show long-term benefits of abbott's mitraclip™ device

New five-year data presented at american college of cardiology scientific sessions (acc.23) and simultaneously published in the new england journal of medicine reinforce the long-term safety and effectiveness of mitraclip for treating secondary mitral regurgitation (mr) results show minimally invasive mitral valve repair in advanced heart failure patients reduces hospitalizations and deaths and provides durable reduction in the severity of mr historically, advanced heart failure patients battling secondary mr (a leaky mitral valve caused by problems affecting other areas of the heart) have been challenging to treat as a result of limited therapy options abbott park, ill., march 5, 2023 /prnewswire/ -- abbott (nyse: abt) today announced late-breaking data for mitraclip™, the leading therapy to treat leaky valves in people with mitral regurgitation (mr), that demonstrate long-term benefits of the device in patients battling heart failure.
ABT Ratings Summary
Quant
ABT Quant Ranking
Sector
Industry
Quant Rating
Quant Score